1                                              NIPT for fetal aneuploidy screening (chromosomes 13, 18,

2                     From a cohort of 125,426 NIPT results, 3757 (3%) were positive for 1 or more aneu

3 used in our standard pipeline for aneuploidy NIPT detected 15/18 (83%) samples with pathogenic rearra

4 s among 39 cases of multiple aneuploidies by NIPT, 18% [95% CI, 7.5%-33.5%]).

5                                       During NIPT in over 4000 prospective pregnancies by parallel se

6                Furthermore, to be effective, NIPT must be able to detect chromosomal rearrangements a

7              Copy-number changes detected in NIPT sequencing data in the known cancer cases were comp

8 ome-wide copy-number changes in the original NIPT samples and in subsequent serial samples from indiv

9  R package that implements several published NIPT analysis methods.

10 ncers most frequently occurred with the rare NIPT finding of more than 1 aneuploidy detected (7 known

11  tumors in pregnant women undergoing routine NIPT.

12                             Because standard NIPT can only detect the majority of larger (>6 Mb) chro

13 y detection on noninvasive prenatal testing (NIPT) and occult maternal malignancies may explain resul

14                Noninvasive prenatal testing (NIPT) for fetal aneuploidy by scanning cell-free fetal D

15 nal cfDNA for non-invasive prenatal testing (NIPT) of aneuploidy is widely available.

16               Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is b

17 uent tumor biopsies were concordant with the NIPT plasma GR profiles.